3 completed, 3 unknown. 3 Phase 2, 3 Phase 3, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Unknown 2, Completed 1 |
| Phase 3 | 3 | Completed 2, Unknown 1 |
| Phase 1 | 2 | Completed 1, Unknown 1 |
Follow SIM0417: new trials by email Literature Review of SIM0417 trials Research Report on SIM0417
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Pharmacokinetics of SIM0417 Combined With Ritonavir in Healthy Elderly Subjects SIM0417/Ritonavir - Elder | Phase 1 | Unknown | Jiangsu Simcere Pharmaceutical Co., Ltd. | 20 | 2023-04-07 | 2023-04-24 |
| A Clinical Study to Evaluate the Efficacy and Safety of SIM0417 Orally Co-Administered With Ritonavir in Symptomatic Adult Participants With Mild to Moderate COVID-19 SIM0417, Placebo - COVID-19 | Phase 2 / Phase 3 | Completed | Jiangsu Simcere Pharmaceutical Co., Ltd. | 1208 | 2022-08-19 | 2023-05-06 |
| Study to Investigate the Mass Balance and Biotransformation of SIM0417 in Healthy Adult Chinese Male Participants SIM0417 - Healthy Male Volunteers | Phase 1 | Completed | Jiangsu Simcere Pharmaceutical Co., Ltd. | 6 | 2022-07-21 | 2022-10-03 |
| To Evaluate SSD8432/Ritonavir in Adults With COVID-19 SSD8432 750mg, SSD8432 placebo - COVID-19 | Phase 2 / Phase 3 | Unknown | Jiangsu Simcere Pharmaceutical Co., Ltd. | 670 | 2022-05-26 | 2022-05-24 |
| Evaluation of SSD8432 and Ritonavir in Adult Subjects With COVID-19 Clinical Study SSD8432 300mg, SSD8432 750mg, SSD8432Placebo - COVID-19 | Phase 2 | Unknown | Jiangsu Simcere Pharmaceutical Co., Ltd. | 72 | 2022-05-20 | 2022-05-24 |
| Study of 0417 Ointment in the Treatment of Atopic Dermatitis 0417, Vehicle of 0417 test product, Tacrolimus Ointment 0.03% - Atopic Dermatitis | Phase 3 | Completed | Fougera Pharmaceuticals Inc. | 899 | 2008-01-01 | 2014-10-09 |
COVID-19 (3) · Dermatitis, Atopic (1)
Jiangsu Simcere Pharmaceutical Co., Ltd. (5) · Fougera Pharmaceuticals Inc. (1)
China (3) · United States (1)
Wei Zhao (2) · Chen Wang (1) · Yumei Yang, Doctor (1) · Yumei Yang, doctor (1)